Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Short Interest Up 126.3% in May

Jasper Therapeutics, Inc. (NASDAQ:JSPRWGet Free Report) saw a significant growth in short interest in May. As of May 31st, there was short interest totalling 8,600 shares, a growth of 126.3% from the May 15th total of 3,800 shares. Based on an average trading volume of 19,000 shares, the short-interest ratio is presently 0.5 days.

Jasper Therapeutics Stock Performance

JSPRW stock remained flat at $0.21 during trading hours on Friday. The company’s stock had a trading volume of 1,439 shares, compared to its average volume of 25,373. The firm’s 50 day simple moving average is $0.18 and its 200-day simple moving average is $0.15. Jasper Therapeutics has a 52-week low of $0.04 and a 52-week high of $0.38.

Jasper Therapeutics Company Profile

(Get Free Report)

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.

Read More

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.